BridgeMD
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
EU CTIS ID: 2025-521710-25-00
What this study is testing
To evaluate efficacy and dose response of ACP-204 30 mg and ACP-204 60 mg compared with placebo in subjects with LBDP (PDDP or DLBP) as measured by the Scale for the Assessment of Positive Symptoms– Lewy Body Dementia Psychosis (SAPS-LBDP), a modified, 9-item scale comprising SAPS Hallucinations and Delusions subscales items
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female ≥55 years to <85 years of age at the Screening visit living in the community or, if permitted by local regulations, in an institutionalized setting
- Can provide written informed consent. If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met: a. The subject’s LAR (or study partner/caregiver, if local regulations allow) must provide written informed consent. b. The subject must provide written (if capable) informed assent per local regulations.
- Meets either the clinical criteria for Parkinson’s disease with dementia as defined by the Movement Disorder Society’s Task Force or the revised clinical criteria for probable dementia with Lewy bodies (DLB) by consensus criteria (Fourth consensus report of the DLB Consortium)
- Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the International Psychogeriatrics Association
You likely can't join if
- Is in hospice, is receiving end-of-life palliative care, or is bedridden
- Has psychotic symptoms that are primarily attributable to delirium, substance abuse, or a medical or psychiatric condition (e.g., schizophrenia, bipolar disorder, delusional disorder) other than dementia
- Is actively suicidal at Visit 1 (Screening) or Visit 2 (Baseline)
- Has a history or current evidence of a serious and/or significant unstable cardiovascular, respiratory, endocrine, gastrointestinal, renal, hepatic, hematologic, immunologic, genitourinary, psychiatric or neurologic (including stroke, chronic seizures, or clinically significant head injury) abnormality or disease or other medical disorder, including cancer or malignancies, that could interfere with subject’s ability to complete the study or comply with study procedures
- Has other clinically significant CNS abnormalities that are most likely contributing to the dementia or findings on MRI or CT
The study team makes the final eligibility decision.
Where it's taking place
- Serbia
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Serbia; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.